Axonis snags $115M to test oral drugs for epilepsy and neuropathic pain

Kyle LaHucik

Senior Reporter

Boston biotech Axonis Therapeutics has raised a $115 million Series A to test whether its oral drug AXN-027 can help patients with focal epilepsy and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Axonis snags $115M to test oral drugs for epilepsy and neuropathic pain

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Ax­o­nis snags $115M to test oral drugs for epilep­sy and neu­ro­path­ic pain

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Axonis snags $115M to test oral drugs for epilepsy and neuropathic pain